SG10201604676WA - Therapy for subarachnoid hemorrhage and ischemia - Google Patents
Therapy for subarachnoid hemorrhage and ischemiaInfo
- Publication number
- SG10201604676WA SG10201604676WA SG10201604676WA SG10201604676WA SG10201604676WA SG 10201604676W A SG10201604676W A SG 10201604676WA SG 10201604676W A SG10201604676W A SG 10201604676WA SG 10201604676W A SG10201604676W A SG 10201604676WA SG 10201604676W A SG10201604676W A SG 10201604676WA
- Authority
- SG
- Singapore
- Prior art keywords
- ischemia
- therapy
- subarachnoid hemorrhage
- subarachnoid
- hemorrhage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570264P | 2011-12-13 | 2011-12-13 | |
| CA2762338A CA2762338C (en) | 2011-12-13 | 2011-12-15 | Therapy for subarachnoid hemorrhage and ischemia |
| US201261617001P | 2012-03-28 | 2012-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604676WA true SG10201604676WA (en) | 2016-07-28 |
Family
ID=51228598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403239UA SG11201403239UA (en) | 2011-12-13 | 2012-12-13 | Therapy for subarachnoid hemorrhage and ischemia |
| SG10201604676WA SG10201604676WA (en) | 2011-12-13 | 2012-12-13 | Therapy for subarachnoid hemorrhage and ischemia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403239UA SG11201403239UA (en) | 2011-12-13 | 2012-12-13 | Therapy for subarachnoid hemorrhage and ischemia |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2800575B1 (en) |
| JP (3) | JP6279483B2 (en) |
| KR (2) | KR20200057802A (en) |
| CN (1) | CN104053448B (en) |
| AU (1) | AU2012354072B2 (en) |
| DK (1) | DK2800575T3 (en) |
| ES (1) | ES2731266T3 (en) |
| IL (1) | IL233103B (en) |
| MX (1) | MX364562B (en) |
| SG (2) | SG11201403239UA (en) |
| WO (1) | WO2013088382A1 (en) |
| ZA (1) | ZA201404636B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2440230T3 (en) | 2009-06-10 | 2021-06-14 | Nono Inc. | Treatment regimes for treatment of neurological disease |
| PL2723363T3 (en) | 2011-06-24 | 2018-12-31 | Nono Inc. | Combination therapy for ischemia |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| CN106661126B (en) | 2014-05-28 | 2021-12-10 | 诺诺公司 | Chloride salt of TAT-NR2B9c |
| CN107312071B (en) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | The therapy of excititoxic associated injury |
| KR20180135493A (en) * | 2016-04-27 | 2018-12-20 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | Treatment of excitatory neurotoxicity-related impairment |
| CN109985047B (en) * | 2017-12-29 | 2021-07-27 | 广州市赛普特医药科技股份有限公司 | Application of 5 alpha-androstane-3 beta, 5,6 beta-triol in preparation of medicine for treating hemorrhagic stroke |
| CN109009111A (en) * | 2018-07-16 | 2018-12-18 | 重庆大学 | Low-field nuclear magnetic resonance cerebral hemorrhage Holter Monitor control system |
| CN113284126B (en) * | 2021-06-10 | 2022-06-24 | 安徽省立医院(中国科学技术大学附属第一医院) | Method for predicting hydrocephalus shunt operation curative effect by artificial neural network image analysis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| ES2446292T3 (en) * | 2007-03-02 | 2014-03-07 | Nono Inc. | Treatment of stroke and other diseases without inhibiting N-type calcium channels |
| PL2440230T3 (en) | 2009-06-10 | 2021-06-14 | Nono Inc. | Treatment regimes for treatment of neurological disease |
-
2012
- 2012-12-13 AU AU2012354072A patent/AU2012354072B2/en active Active
- 2012-12-13 ES ES12857611T patent/ES2731266T3/en active Active
- 2012-12-13 SG SG11201403239UA patent/SG11201403239UA/en unknown
- 2012-12-13 JP JP2014546717A patent/JP6279483B2/en active Active
- 2012-12-13 MX MX2014007031A patent/MX364562B/en active IP Right Grant
- 2012-12-13 DK DK12857611.3T patent/DK2800575T3/en active
- 2012-12-13 SG SG10201604676WA patent/SG10201604676WA/en unknown
- 2012-12-13 WO PCT/IB2012/057259 patent/WO2013088382A1/en active Application Filing
- 2012-12-13 CN CN201280061924.1A patent/CN104053448B/en active Active
- 2012-12-13 KR KR1020207014227A patent/KR20200057802A/en not_active Application Discontinuation
- 2012-12-13 EP EP12857611.3A patent/EP2800575B1/en active Active
- 2012-12-13 KR KR1020147019192A patent/KR102114490B1/en active IP Right Grant
-
2014
- 2014-06-12 IL IL233103A patent/IL233103B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04636A patent/ZA201404636B/en unknown
-
2017
- 2017-11-10 JP JP2017217549A patent/JP6741642B2/en active Active
-
2020
- 2020-05-15 JP JP2020085748A patent/JP2020128419A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL233103A0 (en) | 2014-07-31 |
| ZA201404636B (en) | 2015-10-28 |
| EP2800575A4 (en) | 2015-09-23 |
| KR20140108266A (en) | 2014-09-05 |
| AU2012354072A1 (en) | 2014-07-03 |
| CN104053448B (en) | 2017-04-05 |
| CN104053448A (en) | 2014-09-17 |
| JP6741642B2 (en) | 2020-08-19 |
| KR102114490B1 (en) | 2020-05-25 |
| MX2014007031A (en) | 2015-02-20 |
| JP2020128419A (en) | 2020-08-27 |
| AU2012354072B2 (en) | 2017-04-27 |
| ES2731266T3 (en) | 2019-11-14 |
| WO2013088382A1 (en) | 2013-06-20 |
| MX364562B (en) | 2019-04-30 |
| EP2800575A1 (en) | 2014-11-12 |
| JP2018052962A (en) | 2018-04-05 |
| KR20200057802A (en) | 2020-05-26 |
| JP6279483B2 (en) | 2018-02-14 |
| SG11201403239UA (en) | 2014-09-26 |
| DK2800575T3 (en) | 2019-07-01 |
| EP2800575B1 (en) | 2019-05-22 |
| IL233103B (en) | 2021-03-25 |
| JP2015501834A (en) | 2015-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181526T1 (en) | Combination therapy for ischemia | |
| ZA201309056B (en) | Surgical fastening | |
| EP2739144A4 (en) | Compounds and therapeutic uses thereof | |
| EP2739221A4 (en) | Surgical anchor | |
| ZA201305897B (en) | Combination therapy | |
| EP2720631A4 (en) | Surgical alignment using references | |
| ZA201404636B (en) | Therapy for subarachnoid hemorrhage and ischemia | |
| GB201114212D0 (en) | Therapeutic agents | |
| HK1201454A1 (en) | Therapeutic agents and uses thereof | |
| ZA201400120B (en) | Combination therapy | |
| GB201119401D0 (en) | Therapeutic agents | |
| PL2723330T3 (en) | Vasoconstrictor-containing agent for combination therapy | |
| EP2701744A4 (en) | Combination therapy | |
| EP2750508A4 (en) | Therapeutic compounds and methods | |
| EP2744420A4 (en) | Methods and devices for manipulating and fastening tissue | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents | |
| GB201214985D0 (en) | Modified therapeutic agents | |
| GB201213712D0 (en) | Modified therapeutic agents | |
| GB201110895D0 (en) | Therapeutic use | |
| GB201014963D0 (en) | Therapeutic agents | |
| GB201114226D0 (en) | Combination therapy | |
| GB201012101D0 (en) | Therapeutic agents | |
| GB201012102D0 (en) | Therapeutic agents |